ORION BIOTECHNOLOGY WELCOMES NEW MEMBERS OF SCIENTIFIC ADVISORY BOARD
Ottawa, Canada, April 13, 2021 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a clinical stage biotechnology company focused on precision engineering small protein therapeutics, today announced the addition of four experts to further strengthen its Scientific Advisory Board (SAB). These new SAB members include Dr. Christian Heinis, Dr. Laurent Jespers, Dr. Sebastian Stintzing and Dr. Josep Tabernero.
The Orion Biotechnology SAB is comprised of leading experts in cell receptor pharmacology, biochemistry, translational medicine and research and development (R&D) in oncology and immunology. These individuals serve as key resources for Orion Biotechnology, providing insights as well as offering advice on the company’s drug discovery strategy and technology.
“We are honoured to welcome Drs. Heinis, Jespers, Stintzing and Tabernero as members of our SAB. Their input will prove invaluable as we begin the next phase of our development” said Dr. Ian McGowan – Chief Medical Officer.
“Each member’s expertise will expand our knowledge base and further inform our research and clinical development activities, going forward.” added Dr. Oliver Hartley – VP, Drug Discovery.
Orion Biotechnology is pioneering a new analog-based approach to targeting high-value G-Protein Coupled Receptors (GPCRs) that utilizes native peptide ligands as a scaffold on which to precision engineer drug leads with enhanced potency and tailored signalling activity. This approach uniquely positions Orion to focus on complex GPCRs which have not been successfully drugged by standard discovery approaches, including small molecules and monoclonal antibodies.
About Orion Biotechnology’s New Scientific Advisory Board (SAB) Members
Dr. Christian Heinis is a Professor in Bioorganic Chemistry at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland. His laboratory is developing combinatorial methods for creating therapeutics based on cyclic peptides and macrocyclic compounds. He has over 15 years of experience in peptide engineering, in vitro evolution, and drug development. Dr. Heinis is a co-founder of Bicycle Therapeutics, and co-director of the NCCR Chemical Biology, a research network of around twenty groups in the Lake Geneva area.
Dr. Heinis was trained in chemistry and biochemistry at the ETH Zurich. He did his PhD with Prof. Dario Neri (ETH Zurich), a first post-doc with Prof. Kai Johnsson (EPFL) and a second post-doc with Sir Greg Winter (LMB-MRC in Cambridge, UK).
Dr. Josep Tabernero is Head of the Medical Oncology Deparment at the Vall d’Hebron University Hospital, Director of the Vall d’Hebron Institute of Oncology (VHIO), and Professor of Medicine at UVic-UCC. He has been a Principal Investigator of several Phase 1 pharmacodynamic studies and translational projects with tumor-directed targeted and immune-based therapies. Dr. Tabernero serves on the Editorial Boards of various top tier…